CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1

Epigenetics

Volumn 7, Issue 4, 2012, Pages 390-399

  Yang, Pei Ming ^a   Lin, Pei Jie ^a   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CD1d; Histone deacetylase inhibitor; Sp1

Indexed keywords

CD1D ANTIGEN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE H3; MESSENGER RNA; MITHRAMYCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; VORINOSTAT;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SOLID TUMOR; TRANSCRIPTION INITIATION; TUMOR CELL;

EID: 84860576653     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.19373     Document Type: Article

References (47)

1. Hansen TH, Huang S, Arnold PL, Fremont DH. Patterns of nonclassical MHC antigen presentation. Nat Immunol 2007; 8:563-8; PMID:17514210; http://dx.doi.org/10.1038/ni1475.
2. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114:1379-88; PMID:15545985.
3. Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol 2011; 140:184-95; PMID:21646050; http://dx.doi.org/10.1016/j. clim.2011.04.017.
4. Bleicher PA, Balk SP, Hagen SJ, Blumberg RS, Flotte TJ, Terhorst C. Expression of murine CD1 on gastrointestinal epithelium. Science 1990; 250:679-82; PMID:1700477; http://dx.doi.org/10.1126/science. 1700477.
5. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, et al. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 1997; 159:1216-24; PMID:9233616.
6. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 2000; 100:37-47; PMID:10809957; http://dx.doi.org/10.1046/j.1365- 2567.2000.00001.x.
7. Mandal M, Chen XR, Alegre ML, Chiu NM, Chen YH, Castaño AR, et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol 1998; 35:525-36; PMID:9809580; http://dx.doi.org/10.1016/S0161-5890(98)00055-8.
8. Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M, Bendelac A. CD1.1 expression by mouse antigenpresenting cells and marginal zone B cells. J Immunol 1998; 160:3121-7; PMID:9531266.
9. Chen QY, Jackson N. Human CD1D gene has TATA boxless dual promoters: an SP1-binding element determines the function of the proximal promoter. J Immunol 2004; 172:5512-21; PMID:15100293.
10. Chen QY, Zhang T, Pincus SH, Wu S, Ricks D, Liu D, et al. Human CD1D gene expression is regulated by LEF-1 through distal promoter regulatory elements. J Immunol 2010; 184:5047-54; PMID:20363964; http://dx.doi.org/10.4049/jimmunol.0901912.
11. Geng Y, Laslo P, Barton K, Wang CR. Transcriptional regulation of CD1D1 by Ets family transcription factors. J Immunol 2005; 175:1022-9; PMID:16002702.
12. Chen Q, Ross AC. Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells. Exp Biol Med 2007; 232:488-94; PMID:17392484.
13. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-603; PMID:15164071; http://dx.doi.org/10.1038/nature02625.
14. Fujita N, Takebayashi S, Okumura K, Kudo S, Chiba T, Saya H, et al. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol 1999; 19:6415-26; PMID:10454587.
15. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80; PMID:11498575; http://dx.doi.org/10.1126/science.1063127.
16. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nat Genet 2003; 34:187-92; PMID:12740577; http://dx.doi. org/10.1038/ng1158.
17. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409:581-9; PMID:17868033; http://dx.doi.org/10.1042/ BJ20070779.
18. Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007; 4:337-43; PMID:17976313.
19. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96:293-304; PMID:16088937; http://dx.doi.org/10.1002/ jcb.20532.
20. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12:634-42; PMID:16428510; http://dx.doi.org/10.1158/1078-0432.CCR-05-1132.
21. Chou CW, Chen CC. HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 2008; 582:4059-65; PMID:19007777; http://dx.doi.org/10.1016/j.febslet.2008.10.048.
22. Maeda T, Towatari M, Kosugi H, Saito H. Upregulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96:3847-56; PMID:11090069.
23. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000; 165:7017-24; PMID:11120829.
24. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321-9; PMID:16024634; http://dx.doi.org/10.1158/0008-5472.CAN-04-4252.
25. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65:11136-45; PMID:16322264; http://dx.doi.org/10.1158/0008- 5472.CAN-05-0599.
26. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241:142-50; PMID:9405248; http://dx.doi.org/10.1006/ bbrc.1997.7786.
27. Schnur N, Seuter S, Katryniok C, Rådmark O, Steinhilber D. The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim Biophys Acta 2007; 1771:1271-82; PMID:17894944.
28. Nunes MJ, Milagre I, Schnekenburger M, Gama MJ, Diederich M, Rodrigues E. Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J Neurochem 2010; 113:418-31; PMID:20096088; http://dx.doi. org/10.1111/j.1471-4159.2010.06612.x.
29. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-74; PMID:17412634; http:// dx.doi.org/10.1016/j.biocel.2007.03.001.
30. Pufahl L, Katryniok C, Schnur N, Sorg BL, Metzner J, Grez M, et al. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3. J Cell Mol Med 2011;In press; PMID:21883892; http://dx.doi.org/10.1111/ j.1582-4934.2011.01420.x.
31. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoterassociated HDAC1/2. Cancer Res 2008; 68:2375-83; PMID:18381445; http://dx.doi.org/10.1158/0008-5472.CAN-07-5807.
32. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003; 983:84-100; PMID:12724214; http://dx.doi.org/10.1111/j.1749-6632.2003.tb05964.x.
33. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84; PMID:16955068; http://dx.doi.org/10.1038/nrd2133.
34. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6:238-43; PMID:20139990; http://dx.doi.org/10.1038/ nchembio.313
35. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121:1138-48; PMID:17455259; http://dx.doi.org/10.1002/ijc.22751.
36. Blackwell L, Norris J, Suto CM, Janzen WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 2008; 82:1050-8; PMID:18455194; http://dx.doi.org/10.1016/j.lfs.2008.03.004.
37. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307:720-8; PMID:12975486; http://dx.doi.org/10.1124/jpet.103.055541.
38. Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, et al. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci 2004; 74:2693-705; PMID:15043985; http://dx.doi.org/10.1016/j.lfs.2003.09.070.
39. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004; 101:15064-9; PMID:15477595; http://dx.doi.org/10.1073/ pnas.0404603101.
40. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One 2011; 6:20702; PMID:21695190; http://dx.doi.org/10.1371/journal.pone.0020702.
41. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 2009; 113:2498-507; PMID:19056691; http://dx.doi.org/10.1182/blood-2008-06-161281.
42. Ozeki M, Shively JE. Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells. J Leukoc Biol 2008; 84:769-79; PMID:18552205; http://dx.doi.org/10.1189/jlb.1207817.
43. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6:1057-65; PMID:20962572; http://dx.doi.org/10.4161/auto.6.8.13365.
44. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008; 99:638-45; PMID:18294290; http://dx.doi.org/10.1111/j.1349-7006.2008.00730.x.
45. Haraguchi K, Takahashi T, Nakahara F, Matsumoto A, Kurokawa M, Ogawa S, et al. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma 2006; 47:2218-23; PMID:17071498; http://dx.doi.org/10.1080/10428190600682688.
46. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003; 17:1068-77; PMID:12764370; http://dx.doi.org/10.1038/sj.leu.2402943.
47. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007; 178:2853-61; PMID:17312129.